🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating worldwide, with estimates suggesting in excess of 82 million infections each year. Notably increased rates are reported in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in the same week. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Outcomes and Global Access

Based on findings released by a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the existing first-line therapy, which uses a dual-drug approach. The study included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians treating patients have expressed hope. Having a single-dose, oral treatment like this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as essential to alleviate the strain of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.